Last November, GlaxoSmithKline reported a disappointing 30 percent effectiveness in a trial for its RTS,S anti-malarial vaccine. RTS,S had been championed as the most promising vaccine for the mosquito-borne disease, which infects 300 to 500 million people a year while killing nearly one million, according to CDC estimates. The news followed reports that malaria is becoming increasingly resistant to existing treatments like Artemisinin.
The world health community is now scrambling to identify new anti-malarial solutions. The need is growing more urgent, says Ming Dao, Principal Investigator for malarial research at MIT's SMART Infectious Disease Interdisciplinary Research Group (ID-IRG).
Learn more about his research from MIT's Industrial Liaison Program.